Reported Earlier, HUTCHMED Presents SAVANNAH Trial Results For Savolitinib + TAGRISSO In MET-Driven NSCLC At European Lung Cancer Congress
Benzinga Newsdesk 1 year ago
News
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of
- SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting
- Long-term survival benefit and safety observed in savolitinib Phase IIIb study in METex14 NSCLC